Equillium, Inc. Common Stock

Compare this stock

EQ Stock Report Card

Today's performance

36%

Performance

Score:

10/100

EQ returned -70.89% in the last 12 months. Based on SPY's performance of -16.09%, its performance is below average giving it a score of 10 of 100.

Analyst Price Targets

Score:

100/100

2 analysts offer 12-month price targets for EQ. Together, they have an average target of 0, the most optimistic target put EQ at 0 within 12-months and the most pessimistic has EQ at 0.

Sentiment

Score:

72/100

EQ had a bullish sentiment score of 71.71% across Twitter and StockTwits over the last 12 months. It had an average of 4.25 posts, 3.92 comments, and 7.17 likes per day.

Technicals

Score:

10/100

EQ receives a 10 of 100 based on 14 indicators. 0 are bullish, 12 are bearish.

Earnings

Score:

10/100

EQ has missed earnings 8 times in the last 20 quarters.

Profit

Score:

10/100

Out of the last 20 quarters, EQ has had 1 profitable quarters and has increased their profits year over year on 1 of them.

Volatility

Score:

34/100

EQ has had a lower than average amount of volatility over the last 12 months giving it a score of 33 of 100.

Equillium, Inc. Common Stock Summary

Nasdaq / EQ

Healthcare

Biotechnology

Equillium, Inc., a clinical-stage biotechnology company, develops and sells products to treat severe autoimmune and inflammatory, or immuno-inflammatory disorders with unmet medical need. The company's lead product candidate is itolizumab (EQ001), a clinical-stage monoclonal antibody that targets the novel immune checkpoint receptor CD6, which is in Phase III clinical trials for the treatment of acute graft-versus-host disease; completed Phase Ib clinical trial for the treatment of asthma disease; and Phase Ib clinical trial for the treatment of and lupus nephritis. It also develops EQ101 for treatment of cutaneous T cell lymphoma and alopecia areata; and EQ102 to treat various gastrointestinal diseases. The company was formerly known as Attenuate Biopharmaceuticals, Inc. and changed its name to Equillium, Inc. in May 2017. Equillium, Inc. was incorporated in 2017 and is headquartered in La Jolla, California.

Power up your portfolio